Skip to main content
SpringerLink
Log in

Epidemiology, Control and Treatment of Multidrug-Resistant Tuberculosis

  • Section 6: Epidemiology, Control and Treatment of Multiresistant Organisms: Gram-Negative Rods and Tuberculosis
  • Short Communication
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kochi A, Vareldzis B, Styblo K. Multidrug resistant tuberculosis and its control. Res Microbiol 1993; 144: 104–10.

    Article  PubMed  CAS  Google Scholar 

  2. Cohn D, Bustreo F, Raviglione M. Drug resistance in tuberculosis: review of worldwide situation and WHO’s global surveillance project. Clin Infect Dis. In press

  3. Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tuber Lung Dis 1995; 76: 487–92

    Article  PubMed  CAS  Google Scholar 

  4. Chan L. Chemotherapy of tuberculosis. In: Davies PDO, editor. Clinical tuberculosis. London: Chapman and Hall Medical, 1994: 141–56.

    Google Scholar 

  5. Crofton J. Failure in the treatment of pulmonary tuberculosis: potential causes and their avoidance. Bull Int Union Tuberc Lung Dis 1980; 55: 93–9.

    CAS  Google Scholar 

  6. Acocella G. Studies of bioavailability in men. Bull Int Union Tuberc Lung Dis 1989; 64: 40–2.

    Google Scholar 

  7. Chaulet P. The supply of antituberculosis drugs and national policies. Tuber Lung Dis 1992; 73: 295–304.

    Article  PubMed  CAS  Google Scholar 

  8. Mazouni L, Tazir M, Boulahbal F, et al. Enquête contrôlée comparant trois régimes de chimiothérapie quotidienne de six mois dans la tuberculose pulmonaire en pratique de routine à Alger. Résultats au 30e mois. Rev Mal Respir 1985; 2: 209–14.

    PubMed  CAS  Google Scholar 

  9. Chaulet P, Boulahbal F. Essai clinique d’une combination en proportions fixes de trois medicaments dans le traitement de la tuberculose. Tuber Lung Dis 1995; 76: 407–12.

    Article  PubMed  CAS  Google Scholar 

  10. Singapore Tuberculosis Service/British Medical Research Council. Five year follow up of a clinical trial of three six-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147–50.

    Google Scholar 

  11. Algerian Working Group/British Medical Research Council Cooperative Study. Short course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weekly duration in Algeria. Tubercle 1991; 72: 88–100.

    Article  Google Scholar 

  12. Berkani M, Chaulet P, Darbyshire JH, et al. Résultats d’un essai thérapeutique comparant un régime de 6 mois à un régime de 12 mois dans la tuberculose pulmonaire au Sahara Algérien. Rapport final: résultats trois ans aprés le début du traitement. Rev Mal Respir 1986; 3: 73–85.

    PubMed  CAS  Google Scholar 

  13. Treatment of tuberculosis: guidelines for national programmes. WHO, Geneva, 1993

  14. Union Internationale contre la tuberculose. Comparaison des régimens d’ethionamide, de pyrazinamide et de cyclosérine dans le traitement de malades atteints de tuberculose pulmonaire et déjà traités antérieurement. Bull Int Union Tuberc Lung Dis 1989; 64: 7–64.

    Google Scholar 

  15. Hong Kong tuberculosis treatment services/British Medical Research Council. A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. Tubercle 1974; 55: 1–27.

    Google Scholar 

  16. Ait Khaled N, Benadjila H, Loucif MS, et al. Enquête contrôlée sur trois régimes de chimiothérapie de réserve (dont un de courte durée) dans la tuberculose pulmonaire. Bull Int Union Tuberc Lung Dis 1976; 51: 99–106.

    Google Scholar 

  17. Crofton J. Multidrug resistance: danger for the Third World. In: Porter JDH, McAdam KPNJ, editors. Tuberculosis back to the future. Chichester: John Wiley and Sons Ltd, 1994; 231–3

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. WHO, Global Tuberculosis Programme, 20, Avenue Appia, CH1211, Geneva 27, Switzerland

    Pierre Chaulet, Mario Raviglione & Flavia Bustreo

Authors
  1. Pierre Chaulet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario Raviglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Flavia Bustreo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaulet, P., Raviglione, M. & Bustreo, F. Epidemiology, Control and Treatment of Multidrug-Resistant Tuberculosis. Drugs 52 (Suppl 2), 103–108 (1996). https://doi.org/10.2165/00003495-199600522-00021

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199600522-00021

Keywords

Search

Navigation